NASDAQ:NUVA - NuVasive Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $63.78
  • Forecasted Upside: 13.60 %
  • Number of Analysts: 11
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.98 (1.78%)

This chart shows the closing price for NUVA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NuVasive Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NUVA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NUVA

Analyst Price Target is $63.78
▲ +13.60% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for NuVasive in the last 3 months. The average price target is $63.78, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 13.60% upside from the last price of $56.14.

This chart shows the closing price for NUVA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 11 contributing investment analysts is to hold stock in NuVasive. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2022Truist FinancialInitiated CoverageBuy$60.00 ➝ $65.00N/A
3/28/2022Wells Fargo & CompanyInitiated CoverageOverweight$58.00High
3/24/2022Needham & Company LLCReiterated RatingBuy$64.00Low
2/24/2022Needham & Company LLCReiterated RatingBuy$64.00High
1/7/2022Morgan StanleyLower Price TargetEqual Weight$62.00 ➝ $60.00Medium
12/21/2021Truist FinancialLower Price TargetBuy$75.00 ➝ $60.00High
12/9/2021Royal Bank of CanadaInitiated CoverageOutperform$60.00Medium
11/10/2021Truist FinancialLower Price TargetBuy$80.00 ➝ $75.00High
11/10/2021Credit Suisse GroupLower Price TargetOutperform$84.00 ➝ $83.00High
11/10/2021UBS GroupLower Price TargetSell$59.00 ➝ $54.00High
11/10/2021CitigroupLower Price TargetBuy$82.00 ➝ $70.00High
11/10/2021Needham & Company LLCLower Price TargetPositive ➝ Buy$73.00 ➝ $64.00High
10/28/2021Loop CapitalInitiated CoverageHoldMedium
10/27/2021Needham & Company LLCLower Price TargetBuy$80.00 ➝ $73.00Low
10/27/2021JMP SecuritiesReiterated RatingHoldMedium
10/14/2021JPMorgan Chase & Co.Lower Price TargetNeutral$70.00 ➝ $60.00High
7/29/2021Needham & Company LLCReiterated RatingBuyHigh
5/7/2021Morgan StanleyBoost Price TargetEqual Weight$70.00 ➝ $74.00Low
5/6/2021Needham & Company LLCBoost Price TargetBuy$70.00 ➝ $80.00High
5/6/2021Piper SandlerBoost Price TargetOverweight$75.00 ➝ $80.00High
4/27/2021Truist FinancialBoost Price Target$68.00 ➝ $80.00High
4/19/2021Morgan StanleyBoost Price TargetEqual Weight$65.00 ➝ $70.00Low
3/26/2021Piper SandlerBoost Price TargetOverweight$68.00 ➝ $75.00Low
3/25/2021CitigroupBoost Price Target$68.00 ➝ $80.00Medium
3/1/2021Piper SandlerBoost Price Target$63.00 ➝ $68.00Low
3/1/2021Morgan StanleyBoost Price TargetEqual Weight$53.00 ➝ $65.00Low
1/29/2021Piper SandlerLower Price TargetOverweight$75.00 ➝ $63.00High
1/6/2021Needham & Company LLCReiterated RatingBuy$74.00N/A
12/16/2020Smith Barney CitigroupUpgradeNeutral ➝ Buy$60.00High
12/15/2020Morgan StanleyBoost Price TargetEqual Weight$52.00 ➝ $53.00Medium
12/15/2020Wells Fargo & CompanyDowngradeEqual Weight ➝ Underweight$48.00Medium
11/2/2020Morgan StanleyLower Price TargetEqual Weight$63.00 ➝ $52.00Medium
10/30/2020BTIG ResearchDowngradeBuy ➝ NeutralHigh
10/30/2020SVB LeerinkLower Price TargetOutperform$70.00 ➝ $65.00High
10/30/2020Robert W. BairdDowngradeOutperform ➝ Neutral$76.00 ➝ $56.00High
10/19/2020Stifel NicolausInitiated CoverageBuy$64.00Low
8/5/2020Northland SecuritiesReiterated RatingHoldHigh
7/21/2020Morgan StanleyReiterated RatingHoldLow
7/21/2020Credit Suisse GroupReiterated RatingBuy$74.00Low
7/20/2020Needham & Company LLCReiterated RatingBuy$74.00High
6/25/2020Northland SecuritiesInitiated CoverageMarket Perform$65.00High
6/23/2020Needham & Company LLCUpgradeHold ➝ Buy$74.00Medium
6/12/2020Credit Suisse GroupReiterated RatingBuy$74.00Low
6/5/2020Wells Fargo & CompanyBoost Price TargetEqual Weight$62.00 ➝ $63.00High
5/29/2020Credit Suisse GroupReiterated RatingBuy$74.00Medium
5/7/2020Credit Suisse GroupReiterated RatingBuy$74.00High
5/7/2020UBS GroupLower Price TargetSell$65.00 ➝ $55.00Medium
5/7/2020CitigroupBoost Price TargetNeutral$55.00 ➝ $58.00Medium
5/7/2020Piper SandlerLower Price TargetOverweight$90.00 ➝ $75.00Medium
5/4/2020JPMorgan Chase & Co.Lower Price TargetNeutral$80.00 ➝ $60.00Medium
4/19/2020Robert W. BairdUpgradeNeutral ➝ OutperformMedium
4/14/2020Piper SandlerReiterated RatingBuy$90.00High
4/14/2020Needham & Company LLCReiterated RatingHoldHigh
4/8/2020Wells Fargo & CompanyLower Price TargetEqual Weight$79.00 ➝ $56.00High
4/8/2020Robert W. BairdUpgradeNeutral ➝ Outperform$82.00 ➝ $66.00High
3/27/2020Morgan StanleyLower Price TargetEqual Weight$82.00 ➝ $63.00Medium
3/27/2020CitigroupLower Price TargetNeutral$68.00 ➝ $55.00High
3/6/2020Credit Suisse GroupLower Price TargetOutperform$92.00 ➝ $86.00High
3/4/2020CitigroupInitiated CoverageNeutral$68.00Medium
2/21/2020Cantor FitzgeraldBoost Price TargetIn-Line ➝ Neutral$68.00 ➝ $85.00High
2/21/2020Credit Suisse GroupBoost Price TargetIn-Line ➝ Outperform$87.00 ➝ $92.00High
1/14/2020Robert W. BairdBoost Price TargetNeutral$74.00 ➝ $82.00Low
1/8/2020Credit Suisse GroupBoost Price TargetOutperform$76.00 ➝ $87.00Low
1/7/2020SunTrust BanksInitiated CoverageBuy$93.00Low
1/2/2020Piper Jaffray CompaniesReiterated RatingBuy$80.00Low
12/17/2019Morgan StanleyBoost Price TargetEqual Weight$73.00 ➝ $82.00Low
12/13/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$72.00 ➝ $92.00High
12/12/2019Wells Fargo & CompanyBoost Price TargetEqual Weight$70.00 ➝ $74.00Low
9/24/2019Royal Bank of CanadaBoost Price TargetOutperform$74.00Low
9/9/2019UBS GroupBoost Price TargetSell$51.00 ➝ $55.00Low
8/9/2019CowenSet Price TargetBuy$75.00Low
8/9/2019BTIG ResearchSet Price TargetBuy$71.00N/A
8/9/2019BMO Capital MarketsBoost Price TargetMarket Perform$54.00 ➝ $68.00Low
8/8/2019Needham & Company LLCReiterated RatingHoldLow
8/7/2019Royal Bank of CanadaSet Price TargetBuy$70.00Low
7/31/2019Piper Jaffray CompaniesSet Price TargetBuy$72.00Low
7/31/2019Royal Bank of CanadaSet Price TargetBuy$70.00Low
7/31/2019Morgan StanleyBoost Price TargetEqual Weight$57.00 ➝ $67.00High
7/29/2019Robert W. BairdDowngradeOutperform ➝ Neutral$66.00Low
7/1/2019BTIG ResearchReiterated RatingBuy$65.00Medium
5/2/2019Cantor FitzgeraldReiterated RatingHold$61.00High
2/12/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$60.00High
2/11/2019Cantor FitzgeraldReiterated RatingHold$50.00High
2/8/2019Needham & Company LLCDowngradeBuy ➝ HoldMedium
1/17/2019BTIG ResearchLower Price TargetBuy$59.00Medium
1/8/2019UBS GroupLower Price TargetSell ➝ Sell$54.00 ➝ $42.00Low
1/2/2019Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$73.00 ➝ $57.00Medium
12/17/2018Credit Suisse GroupInitiated CoverageOutperform$66.00High
11/27/2018UBS GroupInitiated CoverageSell$54.00Low
11/27/2018Royal Bank of CanadaBoost Price TargetOutperform$70.00Low
10/31/2018BMO Capital MarketsLower Price TargetMarket Perform ➝ Market Perform$70.00 ➝ $68.00Low
10/31/2018Morgan StanleyLower Price TargetEqual Weight ➝ Hold$77.00 ➝ $73.00Low
10/31/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$80.00 ➝ $75.00High
10/19/2018Cantor FitzgeraldReiterated RatingHold$58.00Medium
10/17/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$67.00 ➝ $80.00Medium
9/27/2018Robert W. BairdUpgradeNeutral ➝ Outperform$60.00 ➝ $82.00High
9/25/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Hold$55.00 ➝ $77.00Low
9/11/2018CowenBoost Price TargetOutperform$62.00 ➝ $80.00Medium
8/16/2018BTIG ResearchBoost Price TargetBuy$72.00High
8/14/2018Piper Jaffray CompaniesBoost Price TargetOverweight$75.00High
8/1/2018Needham & Company LLCLower Price TargetBuy$69.00 ➝ $67.00High
8/1/2018BTIG ResearchInitiated CoverageBuyHigh
7/31/2018Cantor FitzgeraldReiterated RatingHold$58.00High
6/27/2018Bank of AmericaDowngradeNeutral ➝ UnderperformLow
6/21/2018JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$74.00High
5/31/2018Cantor FitzgeraldInitiated CoverageNeutral$54.00Low
5/2/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$70.00 ➝ $69.00High
5/2/2018BMO Capital MarketsDowngradeOutperform ➝ Market Perform$69.00High
5/2/2018BTIG ResearchReiterated RatingBuy$72.00High
4/4/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$47.00Medium
2/27/2018Robert W. BairdReiterated RatingHold$55.00Low
2/27/2018CowenSet Price TargetBuy$62.00Low
2/27/2018BarclaysReiterated RatingOverweight ➝ Buy$66.00 ➝ $62.00Low
2/27/2018Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$67.00 ➝ $55.00High
2/27/2018SVB LeerinkBoost Price TargetMarket Perform ➝ Market Perform$51.00 ➝ $52.00Low
2/27/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$71.00 ➝ $70.00Low
2/1/2018SVB LeerinkDowngradeOutperform ➝ Market PerformMedium
1/17/2018Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$65.00Medium
1/9/2018Piper Jaffray CompaniesReiterated RatingBuy$90.00High
1/4/2018Needham & Company LLCUpgradeUnderperform ➝ Buy$71.00Low
12/14/2017BMO Capital MarketsReiterated RatingBuy$70.00Medium
12/13/2017BTIG ResearchSet Price TargetBuy$74.00Low
11/10/2017Royal Bank of CanadaLower Price TargetOutperform ➝ Outperform$75.00 ➝ $70.00N/A
10/25/2017BMO Capital MarketsLower Price TargetOutperform$85.00 ➝ $69.00N/A
10/25/2017BTIG ResearchSet Price TargetBuy$74.00N/A
10/25/2017Needham & Company LLCReiterated RatingSellN/A
10/25/2017Wells Fargo & CompanyReiterated RatingOutperform$81.00 ➝ $65.00N/A
10/25/2017JPMorgan Chase & Co.Set Price TargetBuy$78.00N/A
10/19/2017BarclaysLower Price TargetOverweight$80.00 ➝ $65.00N/A
10/12/2017Robert W. BairdSet Price TargetHold$72.00 ➝ $60.00N/A
10/12/2017CowenSet Price TargetBuy$72.00N/A
10/12/2017SVB LeerinkReiterated RatingOutperform$74.00 ➝ $69.00N/A
10/10/2017Royal Bank of CanadaReiterated RatingBuy$75.00N/A
10/6/2017Needham & Company LLCReiterated RatingSellN/A
10/6/2017Morgan StanleyReiterated RatingEqual Weight$81.00 ➝ $70.00N/A
10/4/2017BTIG ResearchReiterated RatingBuy$82.00 ➝ $74.00N/A
10/3/2017Jefferies Financial GroupReiterated RatingBuy$79.00Low
9/28/2017Piper Jaffray CompaniesReiterated RatingBuy$90.00Low
9/21/2017GabelliReiterated RatingBuyLow
9/20/2017SVB LeerinkReiterated RatingOutperform ➝ Buy$87.00 ➝ $74.00Low
9/18/2017CowenReiterated RatingOutperform$83.00High
9/8/2017Royal Bank of CanadaReiterated RatingBuy$75.00Medium
9/7/2017BTIG ResearchInitiated CoverageBuy ➝ Buy$82.00Medium
8/28/2017Needham & Company LLCDowngradeHold ➝ UnderperformLow
8/21/2017Royal Bank of CanadaReiterated RatingBuy$85.00Low
8/9/2017Piper Jaffray CompaniesReiterated RatingOverweight$90.00Low
8/2/2017BarclaysReiterated RatingBuy$80.00Low
7/31/2017GabelliReiterated RatingBuyHigh
7/30/2017CowenReiterated RatingOutperform$90.00 ➝ $83.00Medium
7/30/2017Jefferies Financial GroupReiterated RatingBuy$79.00Medium
7/28/2017Robert W. BairdDowngradeOutperform ➝ Neutral$79.00 ➝ $72.00High
7/28/2017Needham & Company LLCReiterated RatingHoldHigh
7/25/2017Morgan StanleyReiterated RatingEqual Weight$84.00 ➝ $88.00Medium
7/20/2017Royal Bank of CanadaReiterated RatingBuy$85.00Medium
7/5/2017Piper Jaffray CompaniesReiterated RatingOverweight$90.00Medium
6/30/2017Jefferies Financial GroupReiterated RatingBuy$84.00Low
6/28/2017CowenReiterated RatingOutperform$85.00 ➝ $90.00High
6/12/2017Piper Jaffray CompaniesBoost Price TargetOverweight$80.00 ➝ $90.00Medium
6/6/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$76.00 ➝ $85.00Low
(Data available from 5/25/2017 forward)

News Sentiment Rating

0.27 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 13 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 5 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
NuVasive logo
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary implant device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $56.14
Low: $53.62
High: $56.31

50 Day Range

MA: $54.60
Low: $49.51
High: $59.75

52 Week Range

Now: $56.14
Low: $45.45
High: $70.76


449,682 shs

Average Volume

576,277 shs

Market Capitalization

$2.92 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of NuVasive?

The following sell-side analysts have issued research reports on NuVasive in the last twelve months: Citigroup Inc., Credit Suisse Group AG, JMP Securities, JPMorgan Chase & Co., Loop Capital, Morgan Stanley, Needham & Company LLC, Royal Bank of Canada,, Truist Financial Co., UBS Group AG, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for NUVA.

What is the current price target for NuVasive?

0 Wall Street analysts have set twelve-month price targets for NuVasive in the last year. Their average twelve-month price target is $63.78, suggesting a possible upside of 13.6%.
View the latest price targets for NUVA.

What is the current consensus analyst rating for NuVasive?

NuVasive currently has 1 sell rating, 4 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NUVA, but not buy more shares or sell existing shares.
View the latest ratings for NUVA.

How do I contact NuVasive's investor relations team?

NuVasive's physical mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company's listed phone number is (858) 909-1800 and its investor relations email address is [email protected] The official website for NuVasive is Learn More about contacing NuVasive investor relations.